The Vigabatrin REMS Program is required by the FDA to ensure notified risk-benefit choices before starting therapy, and to ensure proper use of vigabatrin while people are treated. It is not feasible for your healthcare provider to understand when vision loss will occur.
It is advised that your doctor test your (or your youngster's) vision prior to or within 4 weeks after beginning SABRIL and a minimum of every 3 months throughout treatment till SABRIL is quit. Tell your doctor if you or your child have any type of adverse effects that troubles you or that does not vanish.
Tell your doctor as soon as possible if seizures get worse. If you should take SABRIL while you are pregnant, you and your medical care company will have to determine. The most common negative effects of SABRIL in adults include: obscured vision, sleepiness, wooziness, problems walking or feeling uncoordinated, drinking (trembling), and exhaustion.